Half-year report · HY
9273.TEDINET S100XK39
Period2025-07-01 → 2025-12-31
Filed2026-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.7bn | 2025-07-01 → 2025-12-31 | Cons. | Net sales |
| Revenue | ¥23.3bn | 2024-07-01 → 2025-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.3bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Operating income | ¥3.2bn | 2025-07-01 → 2025-12-31 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2025-07-01 → 2025-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.4bn | 2024-07-01 → 2025-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.1bn | 2025-07-01 → 2025-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2025-07-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2024-07-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2025-07-01 → 2025-12-31 | Cons. | Profit loss |
| Net income | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Total assets | ¥36.5bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥36.1bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥33.6bn | at 2024-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.0bn | at 2025-12-31 | Cons. | Liabilities |
| Total liabilities | ¥8.0bn | at 2025-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥29.6bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥28.1bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2024-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.2bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.9bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.0bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.7bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.8bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.2bn | at 2024-06-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥360m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.8bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.3bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.7bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥829m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥939m | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥738m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥49.53 | 2025-07-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥86.38 | 2024-07-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.66 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 80.9% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.9% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.1% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-07-01 → 2025-12-31 | −¥649m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-07-01 → 2025-12-31 | −¥649m |
| Reconciling Itemsreconciling | segment profit | 2025-07-01 → 2025-12-31 | ¥46m |
| Drug Substance Sales Businessreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥8.5bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥7.8bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥649m |
| Drug Substance Sales Businessreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥1.8bn |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥4.8bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥4.8bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥1.3bn |
| —segment total | revenue | 2025-07-01 → 2025-12-31 | ¥13.3bn |
| —segment total | revenue external | 2025-07-01 → 2025-12-31 | ¥12.7bn |
| —segment total | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥649m |
| —segment total | segment profit | 2025-07-01 → 2025-12-31 | ¥3.1bn |
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | ¥81m |
| Drug Substance Sales Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥8.0bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥7.4bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| Drug Substance Sales Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.6bn |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.4bn |
| —segment total | revenue | 2024-07-01 → 2024-12-31 | ¥12.9bn |
| —segment total | revenue external | 2024-07-01 → 2024-12-31 | ¥12.3bn |
| —segment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| —segment total | segment profit | 2024-07-01 → 2024-12-31 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 495
| Item | Context | Value | Unit |
|---|---|---|---|
| Other ca | Prior1YearInstant | 221905000 | JPY |
| Other ca | InterimInstant | 147433000 | JPY |
| Current assets | Prior1YearInstant | 26527666000 | JPY |
| Current assets | InterimInstant | 27056045000 | JPY |
| Buildings and structures | Prior1YearInstant | 5654060000 | JPY |
| Buildings and structures | InterimInstant | 5717720000 | JPY |
| Accumulated depreciation buildings and structures | Prior1YearInstant | -2748896000 | JPY |
| Accumulated depreciation buildings and structures | InterimInstant | -2856889000 | JPY |
| Buildings and structures net | Prior1YearInstant | 2905164000 | JPY |
| Buildings and structures net | InterimInstant | 2860830000 | JPY |
| Machinery equipment and vehicles | Prior1YearInstant | 3870459000 | JPY |
| Machinery equipment and vehicles | InterimInstant | 3863955000 | JPY |
| Accumulated depreciation machinery equipment and vehicles | Prior1YearInstant | -2958177000 | JPY |
| Accumulated depreciation machinery equipment and vehicles | InterimInstant | -3086300000 | JPY |
| Machinery equipment and vehicles net | Prior1YearInstant | 912281000 | JPY |
| Machinery equipment and vehicles net | InterimInstant | 777654000 | JPY |
| Tools furniture and fixtures | Prior1YearInstant | 1530744000 | JPY |
| Tools furniture and fixtures | InterimInstant | 1561358000 | JPY |
| Accumulated depreciation tools furniture and fixtures | Prior1YearInstant | -1200143000 | JPY |
| Accumulated depreciation tools furniture and fixtures | InterimInstant | -1253139000 | JPY |
| Tools furniture and fixtures net | Prior1YearInstant | 330600000 | JPY |
| Tools furniture and fixtures net | InterimInstant | 308218000 | JPY |
| Land | Prior1YearInstant | 1807189000 | JPY |
| Land | InterimInstant | 1806926000 | JPY |
| Construction in progress | Prior1YearInstant | 3240308000 | JPY |
| Construction in progress | InterimInstant | 3315403000 | JPY |
| Property plant and equipment | Prior1YearInstant | 9195544000 | JPY |
| Property plant and equipment | InterimInstant | 9069033000 | JPY |
| Other ia | Prior1YearInstant | 8661000 | JPY |
| Other ia | InterimInstant | 7606000 | JPY |
| Intangible assets | Prior1YearInstant | 8661000 | JPY |
| Intangible assets | InterimInstant | 7606000 | JPY |
| Investment securities | Prior1YearInstant | 89928000 | JPY |
| Investment securities | InterimInstant | 119287000 | JPY |
| Deferred tax assets | Prior1YearInstant | 263690000 | JPY |
| Deferred tax assets | InterimInstant | 238609000 | JPY |
| Net defined benefit asset | Prior1YearInstant | 17490000 | JPY |
| Net defined benefit asset | InterimInstant | 8387000 | JPY |
| Other ioa | Prior1YearInstant | 11776000 | JPY |
| Other ioa | InterimInstant | 16918000 | JPY |
| Investments and other assets | Prior1YearInstant | 382886000 | JPY |
| Investments and other assets | InterimInstant | 383202000 | JPY |
| Noncurrent assets | Prior1YearInstant | 9587091000 | JPY |
| Noncurrent assets | InterimInstant | 9459842000 | JPY |
| Assets | Prior1YearInstant | 36114758000 | JPY |
| Assets | InterimInstant | 36515888000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 1567463000 | JPY |
| Notes and accounts payable trade | InterimInstant | 1786951000 | JPY |
| Electronically recorded obligations operating cl | Prior1YearInstant | 448935000 | JPY |
| Electronically recorded obligations operating cl | InterimInstant | 711471000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |